Alex Makhnin

Alex Makhnin

Auto-generated profile, based on publicly available information

Alex Makhnin

Memorial Sloan Kettering Cancer Center 1 Thoracic Oncology Service, Division of Solid Tumor Oncology, Department of Medicine New York, New York

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 June 2021 in Nature Communications
Verified
Journal Article
Open access
PDF file
KPKamrine E. Poels
Kamrine E. Poels
ASAdam J. Schoenfeld
Adam J. Schoenfeld
AMAlex Makhnin
Alex Makhnin
YTYosef Y Tobi
Yosef Y Tobi
YWYuli Wang
Yuli Wang
FMFranziska Michor
Franziska Michor
Despite the clinical success of the third-generation EGFR inhibitor osimertinib as a first-line treatment of EGFR-mutant non-small cell lung cancer (NSCLC), resistance arises due to the acquisition of EGFR second-site mutations and other mechanisms, which necessitates alternative therapies. Dacomitinib, a pan-HER inhibitor, is approved for first-line treatment and results in different acquired EGFR mutations than osimertinib that mediate on-target resistance. A combination of osimertinib and dacomitinib could therefore induce more durable responses by preventing the emergence of resistance. Here we present an integrated computational modeling and experimental approach to identify an optimal dosing schedule for osimertinib and dacomitinib combination therapy. We developed a predictive model that encompasses tumor heterogeneity and inter-subject pharmacokinetic variability to predict tumor evolution under different dosing schedules, parameterized using in vitro dose-response data. This model was validated using cell line data and used to identify an optimal combination dosing schedule. Our schedule was subsequently confirmed tolerable in an ongoing dose-escalation phase I clinical trial (NCT03810807), with some dose modifications, demonstrating that our rational modeling approach can be used to identify appropriate dosing for combination therapy in the clinical setting.

28 June 2024 in Clinical Cancer Research
Verified
Journal Article
Closed access
NCNoura J. Choudhury
Noura J. Choudhury
WLW. Victoria Lai
W. Victoria Lai
AMAlex Makhnin
Alex Makhnin
GHGlenn Heller
Glenn Heller
JEJuliana Eng
Juliana Eng
CRCharles M. Rudin
Charles M. Rudin
Purpose: Recurrent small-cell lung cancer (SCLC) has few effective treatments. The EZH2-SLFN11 pathway is a driver of acquired chemoresistance that may be targeted. Patients and Methods: This phase I/II trial investigated valemetostat, an EZH1/2 inhibitor, with fixed-dose irinotecan in patients with recurrent SCLC. Phase I primary objectives were to assess safety, tolerability, and a recommended phase II dose (RP2D). The phase II primary objective was overall response rate (ORR), with secondary objectives of determining duration of response (DoR), progression-free survival (PFS), and overall survival (OS). Correlative analyses included immunohistochemistry of pretreatment and on-treatment tumor biopsies and pharmacokinetics analysis. Results: Twenty-two patients were enrolled (phase I, n = 12; phase II, n = 10); one withdrew consent prior to treatment. Three dose-limiting toxicities (DLT) in dose-escalation resulted in valemetostat 100 mg orally daily selected as RP2D. Among 21 evaluable patients, the most frequent (≥20%) treatment-related adverse events were diarrhea, fatigue, nausea, and rash; three patients discontinued treatment for toxicity. Three of the first 10 patients in phase II experienced DLTs triggering a stopping rule. The ORR was 4/19 or 21% [95% confidence interval (CI), 6%–46%]. The median DoR, PFS, and OS were 4.6 months, 2.2 months (95% CI, 1.3–7.6 months), and 6.6 months (95% CI, 4.3 to not reached), respectively. SLFN11/EZH2 expression and SCLC subtyping markers did not correlate with response, but MHC-I expression did increase with treatment. Two responders demonstrated subtype switching on treatment. Conclusions: Combination valemetostat and irinotecan was not tolerated but demonstrated efficacy in recurrent SCLC. Valemetostat, combined with agents without overlapping toxicity, warrants further investigation in SCLC.

2 February 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
AEArielle Elkrief
Arielle Elkrief
AMAlex Makhnin
Alex Makhnin
KMKhadeja A. Moses
Khadeja A. Moses
LALinda S. Ahn
Linda S. Ahn
IPIsabel R. Preeshagul
Isabel R. Preeshagul
HYHelena A. Yu
Helena A. Yu
Purpose: Primary and acquired resistance to osimertinib remain significant challenges for patients with EGFR-mutant lung cancers. Acquired EGFR alterations such as EGFR T790M or C797S mediate resistance to EGFR tyrosine kinase inhibitors (TKI) and combination therapy with dual EGFR TKIs may prevent or reverse on-target resistance. Patients and Methods: We conducted two prospective, phase I/II trials assessing combination osimertinib and dacomitinib to address on-target resistance in the primary and acquired resistance settings. In the initial therapy study, patients received dacomitinib and osimertinib in combination as initial therapy. In the acquired resistance trial, dacomitinib with or without osimertinib was administered to patients with EGFR-mutant lung cancers with disease progression on osimertinib alone and evidence of an acquired EGFR second-site mutation. Results: Cutaneous toxicities occurred in 93% (any grade) of patients and diarrhea in 72% (any grade) with the combination. As initial therapy, the overall response to the combination was 73% [95% confidence interval (CI), 50%–88%]. No acquired secondary alterations in EGFR were observed in any patients at progression. In the acquired resistance setting, the overall response was 14% (95% CI, 1%–58%). Conclusions: We observed no acquired secondary EGFR alterations with dual inhibition of EGFR as up-front treatment, but this regimen was associated with greater toxicity. The combination was not effective in reversing acquired resistance after development of a second-site acquired EGFR alteration. Our study highlights the need to develop better strategies to address on-target resistance in patients with EGFR-mutant lung cancers.

1 April 2023
Verified
Other
Open access
AEArielle Elkrief
Arielle Elkrief
AMAlex Makhnin
Alex Makhnin
KMKhadeja A. Moses
Khadeja A. Moses
LALinda S. Ahn
Linda S. Ahn
IPIsabel R. Preeshagul
Isabel R. Preeshagul
HYHelena A. Yu
Helena A. Yu
Supplemental Figure 2. Dose modifications of Dacomitinib +/- Osimertinib (acquired resistance study).

1 April 2023
Verified
Other
Open access
AEArielle Elkrief
Arielle Elkrief
AMAlex Makhnin
Alex Makhnin
KMKhadeja A. Moses
Khadeja A. Moses
LALinda S. Ahn
Linda S. Ahn
IPIsabel R. Preeshagul
Isabel R. Preeshagul
HYHelena A. Yu
Helena A. Yu
Supplemental Figure 2. Dose modifications of Dacomitinib +/- Osimertinib (acquired resistance study).

1 April 2023
Verified
Other
Open access
AEArielle Elkrief
Arielle Elkrief
AMAlex Makhnin
Alex Makhnin
KMKhadeja A. Moses
Khadeja A. Moses
LALinda S. Ahn
Linda S. Ahn
IPIsabel R. Preeshagul
Isabel R. Preeshagul
HYHelena A. Yu
Helena A. Yu
Supplemental Figure 3. A. Median progression-free survival and B. Overall survival for patients enrolled in the initial therapy study